中外医学研究2025，Vol.23Issue(26)：181-184,4.DOI:10.14033/j.cnki.cfmr.2025.26.048
血管性血友病因子裂解酶与血栓性微血管病诊治进展
Progress in the Diagnosis and Treatment of Hemophilia Factor Lyase and Thrombotic Microvascular Disease
摘要
Abstract
Thrombotic microangiopathy(TMA)is a group of diseases characterized by microvascular embolism.Its etiology and pathogenesis are complex and diverse,including primary thrombotic microangiopathy and secondary thrombotic microangiopathy.There is a close correlation between A Disintegrin and Metalloproteinase with Thrombospondin Type 1 motif,member 13(ADAMTS13)and TMA.There are various methods for detecting its activity,and it has positive clinical significance in disease diagnosis,prognosis assessment,and disease differentiation.The role of ADAMTS13 in the diagnosis and treatment of thrombotic thrombocytopenic purpura is relatively clear,and it may also play an important role in other types of thrombotic microvascular diseases.The determination of its activity helps to distinguish different types of hemolytic uremic syndrome and other diseases,and provides a basis for treatment.The activity of ADAMTS13 has been reduced to varying degrees in thrombotic microvascular diseases such as disseminated intravascular coagulation,systemic lupus erythematosus nephritis,and severe liver injury,and it may serve as an auxiliary diagnostic indicator for such diseases.关键词
血管性血友病因子裂解酶/血栓性微血管病/检测/诊治Key words
A Disintegrin and Metalloproteinase with Thrombospondin Type 1 motif,member 13/Thrombotic microangiopathy/Detection/Diagnosis and treatment引用本文复制引用
晏妮,白俊,徐泽坤..血管性血友病因子裂解酶与血栓性微血管病诊治进展[J].中外医学研究,2025,23(26):181-184,4.基金项目
甘肃省重点研发计划项目(20YF8WA019) （20YF8WA019）
